[6-K] Haleon plc American Current Report (Foreign Issuer)

Rhea-AI Filing Summary

Haleon has announced a significant share buyback transaction as part of its program announced on March 28, 2025. On June 20, 2025, the company purchased 1,016,186 ordinary shares for cancellation at prices ranging from 382.70p to 388.00p per share, with a volume-weighted average price of 385.10p.

Following the settlement, Haleon's registered share capital consists of 8,991,557,409 ordinary shares of £0.01 each, with 4,080,205 held as treasury shares. The total number of voting rights is now 8,987,477,204.

Haleon, a global consumer health leader listed on LSE/NYSE, maintains a portfolio across six major categories:

• Oral Health
• Vitamins, Minerals and Supplements (VMS)
• Pain Relief
• Respiratory Health
• Digestive Health
• Therapeutic Skin Health

The company's brand portfolio includes notable names such as Advil, Centrum, Sensodyne, and Voltaren.

Positive

• Haleon executed a share buyback of 1,016,186 shares at an average price of 385.10p, demonstrating confidence in company valuation and commitment to returning capital to shareholders

Negative

• None.

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of June 2025

Commission File Number: 001-41411

Haleon plc

(Translation of registrant’s name into English)

Building 5, First Floor, The Heights,

Weybridge, Surrey, KT13 0NY

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

Form 20-F ☒ Form 40-F ☐

EXHIBIT INDEX

Exhibit Number	Description
99.1	23 June 2025 - “Transaction in Own Shares”

99.1

Haleon plc: Transaction in own shares

23 June 2025: Haleon plc (the "Company" or "Haleon") today announces the purchase of the following number of ordinary shares of £0.01 each in the Company (the "Shares") for cancellation under its share buyback programme announced on 28 March 2025 (the "Buyback Programme").

Date of purchase:	20 June 2025
Number of Shares purchased:	1,016,186
Highest price paid per share (p):	388.00
Lowest price paid per share (p):	382.70
Volume weighted average price paid per share (p):	385.10

Following the settlement of the above, the Company's registered share capital is 8,991,557,409 ordinary shares of £0.01 each, of which 4,080,205 are held as treasury shares. Therefore, the number of ordinary shares with voting rights is 8,987,477,204 and this figure may be used by shareholders to determine if they are required to notify their interest, or a change to their interest, in Haleon under the FCA's Disclosure Guidance and Transparency Rules.

In accordance with Article 5(1)(b) of Regulation (EU) No 596/2014 as it applies in the UK(the Market Abuse Regulation), a full breakdown of the individual trades is available at the link below:

http://www.rns-pdf.londonstockexchange.com/rns/8575N_1-2025-6-20.pdf

This announcement does not constitute, or form part of, an offer or any solicitation of an offer for securities in any jurisdiction.

This announcement and individual trade breakdown will also be available on the Company's website at: www.haleon.com/investors.

Enquiries

Investors		Media
Jo Russell	+44 7787 392441	Zoë Bird	+44 7736 746167
Rakesh Patel	+44 7552 484646	Victoria Durman	+44 7894 505730
Emma White	+44 7823 523562
Email: investor-relations@haleon.com		Email: corporate.media@haleon.com

 

About Haleon

Haleon (LSE/NYSE: HLN) is a global leader in consumer health, with a purpose to deliver better everyday health with humanity. Haleon's product portfolio spans six major categories - Oral Health, Vitamins, Minerals and Supplements (VMS), Pain Relief, Respiratory Health, Digestive Health and Therapeutic Skin Health and Other. Its long-standing brands - such as Advil, Centrum, Otrivin, Panadol, parodontax, Polident, Sensodyne, Theraflu and Voltaren - are built on trusted science, innovation and deep human understanding.

For more information, please visit www.haleon.com.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

		HALEON PLC (Registrant)
Date: June 23, 2025	By:	/s/ Amanda Mellor
		Name:	Amanda Mellor
		Title:	Company Secretary

FAQ

How many shares did HLN buy back on June 20, 2025?

Haleon (HLN) purchased 1,016,186 shares on June 20, 2025, as part of its share buyback programme announced on March 28, 2025. The volume weighted average price paid per share was 385.10 pence.

What is HLN's total number of voting shares after the June 2025 buyback?

After the share buyback settlement, Haleon has 8,987,477,204 ordinary shares with voting rights. The company's total registered share capital is 8,991,557,409 ordinary shares of £0.01 each, with 4,080,205 shares held as treasury shares.

What was the price range for HLN's share buyback on June 20, 2025?

During the June 20, 2025 buyback, Haleon paid between 382.70 pence (lowest price) and 388.00 pence (highest price) per share, with a volume weighted average price of 385.10 pence per share.

When did HLN announce its current share buyback program?

Haleon announced its current share buyback programme on March 28, 2025. This program is currently ongoing with the latest reported purchase occurring on June 20, 2025.

What are HLN's major product categories as of 2025?

Haleon's product portfolio spans six major categories: Oral Health, Vitamins, Minerals and Supplements (VMS), Pain Relief, Respiratory Health, Digestive Health, and Therapeutic Skin Health and Other. The company's brands include Advil, Centrum, Otrivin, Panadol, parodontax, Polident, Sensodyne, Theraflu, and Voltaren.